Navigation Links
Amgen to Present at the Thomas Weisel Healthcare Conference
Date:9/8/2009

THOUSAND OAKS, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Thomas Weisel Healthcare Conference on Friday, Sept. 11, 2009, at the Four Seasons in Boston, Mass. beginning at 8:35 a.m. Eastern Time. Roy Baynes, M.D. Ph.D., vice president of Global Development for Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.

Information regarding presentation time, webcast availability, and webcast links are available on Amgen's Investor Relations Events Calendar.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

    CONTACT: Amgen, Thousand Oaks
    David Polk, 805-447-4613 (media)
    Arvind Sood, 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Amgen to Present at the Baird Healthcare Conference
2. Amgen to Discuss Denosumab Data at Todays Advisory Committee for Reproductive Health Drugs
3. Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
4. Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29
5. Amgen Announces Webcast of 2009 Second Quarter Financial Results
6. Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium
7. Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)
8. Amgen Appoints Rebecca M. Henderson to the Companys Board of Directors
9. 34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence
10. AUDIO from Medialink and Amgen: Experts Agree Infection in Cancer Patients Impacts Treatment Success
11. Amgen to Present at the Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, ... conference “ Preventing Hospital Readmissions Through Discharge Planning ” with noted expert Sue ... ET. This conference discusses strategies to prevent readmissions in light of the most ...
(Date:3/29/2017)... ... 29, 2017 , ... During the last week of March, Chad Kawa, MD ... individuals in the local community. , Colon cancer is the second leading cause ... cancer while it is small, confined and easier to treat. If you are 50 ...
(Date:3/29/2017)... San Diego, CA (PRWEB) , ... March 29, 2017 , ... ... meningiomas(1,2), and up to 300,000 people each year develop other types of metastatic brain ... spread quickly throughout the brain(3). As efforts focus on finding more effective treatment options, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an Atlanta-based ... Pet Protect Law that assists dog owners in creating legally-enforceable pet trusts for ... taking the natural next step to protect their new companion. Says Evan Dunbar, CEO ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL ... that Mercy Medical Center will serve as the official title sponsor of the Baltimore ... June 25, 2017, thousands of women will walk or run the course around the ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... March 30, 2017  Lannett Company, Inc. (NYSE: ... made a $25 million payment against its existing revolving ... combined with the $75 million payment we made earlier ... million in annualized cash interest expense, at current rates" ... Lannett.  "Our business is solid and we continue to ...
(Date:3/30/2017)... Revenue Prospects by Product Type (Metered Dose ... Geography Respiratory Inhalers - our new study reveals trends, ... market heading? If you are involved in this sector you must ... the potential revenues streams to 2027, assessing data, trends, opportunities and ... ...
(Date:3/30/2017)... 30, 2017  Purcell Julie & Lefkowitz LLP, a class ... a potential breach of fiduciary duty claim involving the board ... ). If you are a shareholder of ... this investigation, free of charge, please visit us at: ... http://pjlfirm.com/synergy-pharmaceuticals-inc/ ...
Breaking Medicine Technology: